Vivimed Labs Stock Falls to 52-Week Low Amidst Weak Financial Metrics

Stock Price Movement and Market Context

On 1 Jan 2026, Vivimed Labs’ share price declined by 4.99%, underperforming its sector by 4.72%. The stock has been on a downward trajectory for seven consecutive trading days, resulting in a cumulative loss of 30.03% over this period. This decline has pushed the stock to its lowest level in the past year, closing near ₹7.50, well below its 52-week high of ₹24.01.

Despite the broader market showing resilience, with the Sensex trading marginally higher at 85,228.74 points—just 1.09% shy of its 52-week peak—the stock’s performance remains subdued. The Sensex is currently supported by bullish moving averages, trading above its 50-day and 200-day moving averages, while mid-cap stocks are leading gains with a 0.07% rise in the BSE Mid Cap index. In contrast, Vivimed Labs has failed to mirror this positive momentum.

Technically, the stock is trading above its 20-day, 50-day, 100-day, and 200-day moving averages but remains below its 5-day moving average, indicating short-term selling pressure despite some longer-term support levels.

Financial Performance and Fundamental Concerns

Vivimed Labs’ financial metrics reveal several areas of concern that have contributed to the stock’s decline. The company has not declared any financial results in the last six months, which has raised questions about its transparency and financial health. This absence of recent disclosures has coincided with a downgrade to a Strong Sell rating by MarketsMOJO, with a Mojo Score of 24.0 as of 22 Dec 2025.

The company’s long-term fundamentals appear weak, with a Market Cap Grade of 4 indicating limited market capitalisation strength. Its ability to service debt is notably strained, reflected in a high Debt to EBITDA ratio of 12.57 times, signalling significant leverage and potential liquidity pressures.

Profitability metrics also paint a challenging picture. The average Return on Equity (ROE) stands at a modest 1.75%, indicating low returns generated on shareholders’ funds. The company’s half-yearly Profit After Tax (PAT) for June 2023 was negative at ₹-281.57 crores, representing a decline of 34.93% compared to previous periods.

Additionally, the Debt-Equity ratio reached a peak of 9.60 times in the half-year period, underscoring the company’s heavy reliance on borrowed funds. The Debtors Turnover ratio was recorded at a low 2.44 times, suggesting slower collection cycles and potential working capital inefficiencies.

Stock Valuation and Risk Profile

Over the past year, Vivimed Labs’ stock has generated a flat return of 0.00%, starkly contrasting with the Sensex’s 8.61% gain over the same period. This stagnation, combined with a 267.9% decline in profits, highlights the stock’s underperformance and elevated risk profile.

The stock’s current valuation is considered risky relative to its historical averages, reflecting investor caution amid the company’s financial difficulties and lack of recent earnings updates. The downgrade to a Strong Sell Mojo Grade further emphasises the market’s concerns regarding the company’s prospects and financial stability.

Summary of Key Metrics

To summarise, Vivimed Labs’ key financial and market indicators as of early 2026 are as follows:

• Stock price at 52-week low: ₹7.50


• 52-week high: ₹24.01


• Seven-day consecutive decline: -30.03%


• Mojo Score: 24.0 (Strong Sell)


• Debt to EBITDA ratio: 12.57 times


• Return on Equity (average): 1.75%


• Half-year PAT (June 2023): ₹-281.57 crores (-34.93%)


• Debt-Equity ratio (half-year): 9.60 times


• Debtors Turnover ratio (half-year): 2.44 times


• One-year stock return: 0.00% vs Sensex 8.61%

Market Environment and Comparative Performance

While the broader market environment remains relatively positive, with the Sensex near its 52-week high and mid-cap stocks leading gains, Vivimed Labs’ performance diverges significantly. The stock’s underperformance relative to sector peers and the benchmark index reflects the company’s ongoing financial difficulties and subdued investor confidence.

The stock’s current position below short-term moving averages, despite being above longer-term averages, suggests that recent market sentiment has been cautious, with selling pressure dominating in the near term.

Conclusion

Vivimed Labs’ fall to its 52-week low is a reflection of its challenging financial position, absence of recent earnings disclosures, and elevated leverage. The stock’s performance contrasts with the broader market’s positive trend, underscoring the company-specific issues that have weighed on investor sentiment. The combination of weak profitability, high debt levels, and stagnant stock returns has culminated in a Strong Sell rating, highlighting the need for careful monitoring of the company’s financial developments going forward.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →